Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.

NDAQ:AGIO - Post by User

Agios Pharmaceuticals Inc

Bullboard Posts

Next >>

Post by AviseAnalyticson Feb 08, 2022 9:02am

112 Views

Post# 34407927

5 BIOTECH STOCKS WITH MAJOR UPCOMING CATALYSTS

$AGIO $CYTK $ADGI $PHAT $ICPT

Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table.

The covered Companies have major upcoming catalysts such as an impending FDA approval, drug launch, data readouts, initiation of clinical trials and IND submission to look forward to.

Learn More:
https://www.aviseanalytics.com/5-biotech-stocks-with-major-upcoming-catalysts/

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant